Translate

Friday, September 14, 2018

thumbnail

GKOS Glaukos Corporation gains 49% Sep 14, 2018

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.http://www.priceseries.com/trade/GKOS-Glaukos-Corporation-stock-gains-49-percent-a-Trade-Record-by-priceSeries-2018082220180914.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive